Soil Air-Water Properties in Catena of Sepopol Lowland

In the sequence of soil composed of black earths, deluvial soils, organic soils covered with a thin layer of mineral-organic deposit and moorsh soils, soil texture, bulk density, content of organic carbon and organic matter, total porosity, total and readily available water as well as resources of organic matter and water in 0-25 cm and 0-100 cm layers of the soil profile were studied. A catenal variabilities of organic matter content and physical-water properties were found. Physical properties and the contents of total and readily available water depended on soil texture, organic matter content and location in a relief. Total porosity, field water capacity and volume of macropores were positively correlated with organic matter content, and negatively with bulk density. Differences in studied properties between the pedons of black earths and deluvial soils were small, whereas these differences between deluvial and moorsh soils were distinct. In the development of water resources in the profiles of these soils, presence of organic subsoil with high retention capacity played the important role. The studied soils had unfavorable distribution of soil pores, resulting from a small volume of air pores

Predictive role of monocyte count for significant coronary artery disease identification in patients with stable coronary artery disease

Background: The coronary artery disease (CAD) remains the leading cause of morbidity that is characterized by broad spectrum of symptoms. Up to 30% of performed angiographies reveal normal coronary arteries. The aim of the study was to find simple predictor for significant epicardial artery stenosis among patients with chronic coronary syndrome. Methods: There were 187 patients (131 (709%) men and 56 (30%) women) in the median (Q1–Q3) age of 67 [58–72] presenting with stable CAD symptoms enrolled into the present retrospective analysis. The demographical, clinical and laboratory characteristics between patients with normal and significant coronary artery stenosis were compared. Results: The multivariable analysis revealed coexistence of hypercholesterolemia as significant differentiation factor (odds ratio [OR]: 4.38, 95% confidence interval [CI]: 1.78–10.80, p = 0.001) for significant CAD and inverse relation to serum high density lipoprotein (OR: 0.19, 95% CI: 0.05–0.72, p = 0.015) and relation to creatinine concentration (OR: 1.03, 95% CI: 1.00–1.05, p = 0.012). Among whole peripheral blood count analysis, the significant relation was noticed to be hemoglobin concentration (OR: 1.09, 95% CI: 1.10–1.18, p = 0.022) and monocyte count (OR: 32.3, 95% CI: 1.09–653.6, p = 0.017). Receiver operator curve revealed (AUC: 0.641, p = 0.001) with the optimal cut-off value above 0.45 K/uL for monocyte, yelding sensitivity of 81.82% and specificity of 58.06%. Conclusions: The peripheral monocyte count above 0.45 k/uL may be considered as a predictor of significant coronary artery disease in symptomatic patients with chronic coronary syndrome

Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

Background: Ion channel inhibition may offer protection against coronavirus disease 2019 (COVID-19). Inflammation and reduced platelet count occur during COVID-19 but precise quantification of risk thresholds is unclear. The Recov ery-SIRIO study aimed to assess clinical effects of amiodarone and verapamil and to relate patient phenotypes to outcomes. Methods: RECOVERY-SIRIO is a multicenter open-label 1:1:1 investigator-initiated randomized trial with blinded event adjudication. A sample of 804 symptomatic hospitalized nonintensive-care COVID-19 patients, follow-up for 28 days was initially planned. Results: The trial was stopped when a total of 215 patients had been randomized to amiodarone (n = 71), verapamil (n = 72) or standard care alone (n = 72). At 15 days, the hazard ratio (hazard ratio [HR], 95% confidence interval [CI]) for clinical improvement was 0.77 (0.52–1.14) with amiodarone and 0.97 (0.81–1.17) with verapamil as compared to usual care. Clinically relevant associations were found between mortality or lack of clinical improvement and higher peak C-reactive protein (CRP) levels or nadir platelet count at 7, 10 and 15 days. Mortality rate increased by 73% every 5 mg/dL increment in peak CRP (HR 1.73, 95% CI 1.27–2.37) and was two-fold higher for every decrement of 100 units in nadir platelet count (HR 2.19, 95% CI 1.37–3.51). By cluster analysis, thresholds of 5 mg/dL for peak CRP and 187 × 103/mcL for nadir platelet count identified the phenogroup at greatest risk of dying. Conclusions: In this randomized trial, neither amiodarone nor verapamil were found to significantly accelerate short-term clinical improvement. Peak CRP and nadir platelet counts were associated with increased mortality both in isolation and by cluster analysis

Foto-obrazy architektury: Fotografia jako medium referujące i projektujące architekturę

Praca recenzowana / peer-reviewed paperNiniejszy zbiór prac teoretycznych, fotoesejów i kronika studenckich konkursów fotograficznych organizowanych od 2008 roku na Wydziale Architektury i Sztuk Pięknych Krakowskiej Akademii im. Andrzeja Frycza Modrzewskiego, ma być zapisem refleksji związanych ze specyficzną, jak dotąd mało zbadaną a wszechobecną częścią teorii architektury, jaką jest fotografia. Jej szczególna odmiana ściśle związana ze sztuką budowania jest określana mianem fotografii architektonicznej, jednakże niniejsza monografia nie została tą definicją ograniczona.This book contains a selection of theoretical works and photo essays as well as a chronicle of photo competitions organised in the Faculty of Architecture and Fine Arts at Andrzej Frycz Modrzewski Krakow University since 2008, which is meant as the record of thoughts related to the specific, omnipresent though little examined so far, realm of the theory of architecture, i.e. photography. Its specific variant closely related to the building practice is called architectural photography. This monograph, however, is not restricted by means of the said definition and attempts at a slightly broader description of the phenomenon, reaching beyond its boundaries.Monografia powstała w ramach projektu badawczego nr WAiSP/DS/4/201

NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods

Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submit- Avenue, Silver Spring, Maryland 20993; 22Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia; 23Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovacˇ ic´ a 1, 10 000 Zagreb, Croatia; 24Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303; 25glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany; 26Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada; 27Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739–8530 Japan; 28ImmunoGen, 830 Winter Street, Waltham, Massachusetts 02451; 29Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31–126 Krakow, Poland; 30Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287; 31Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704; 32Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363–883 Korea (South); 33Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363–700, Korea (South); 34Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands; 35Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom; 36Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia; 37Proteomics, Central European Institute for Technology, Masaryk University, Kamenice 5, A26, 625 00 BRNO, Czech Republic; 38Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany; 39Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany; 40AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom; 41Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033; 42Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103; 43MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108; 44MSD, Molenstraat 110, 5342 CC Oss, The Netherlands; 45Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, 5–1 Higashiyama, Myodaiji, Okazaki 444–8787 Japan; 46Graduate School of Pharmaceutical Sciences, Nagoya City University, 3–1 Tanabe-dori, Mizuhoku, Nagoya 467–8603 Japan; 47Medical & Biological Laboratories Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464–0858 Japan; 48National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom; 49Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158–8501 Japan; 50New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938; 51New York University, 100 Washington Square East New York City, New York 10003; 52Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom; 53GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland; 54Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695; 55Pantheon, 201 College Road East Princeton, New Jersey 08540; 56Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810; 57Proteodynamics, ZI La Varenne 20–22 rue Henri et Gilberte Goudier 63200 RIOM, France; 58ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545; 59Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan; 60Children’s GMP LLC, St. Jude Children’s Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105; 61Sumitomo Bakelite Co., Ltd., 1–5 Muromati 1-Chome, Nishiku, Kobe, 651–2241 Japan; 62Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands; 63Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139; 64Department of Chemistry and Biochemistry, Texas Tech University, 2500 Broadway, Lubbock, Texas 79409; 65Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085; 66United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India; 67Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 68Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 69Department of Chemistry, University of California, One Shields Ave, Davis, California 95616; 70Horva´ th Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; 71Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary; 72Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711; 73Proteomics Core Facility, University of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden; 74Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden; 75Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden; 76Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany; 77Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; 78Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France; 79Natural and Medical Sciences Institute, University of Tu¨ bingen, Markwiesenstrae 55, 72770 Reutlingen, Germany; 80Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; 81Division of Bioanalytical Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands; 82Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757; 83Zoetis, 333 Portage St. Kalamazoo, Michigan 49007 Author’s Choice—Final version open access under the terms of the Creative Commons CC-BY license. Received July 24, 2019, and in revised form, August 26, 2019 Published, MCP Papers in Press, October 7, 2019, DOI 10.1074/mcp.RA119.001677 ER: NISTmAb Glycosylation Interlaboratory Study 12 Molecular & Cellular Proteomics 19.1 Downloaded from https://www.mcponline.org by guest on January 20, 2020 ted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide communityderived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods. Molecular & Cellular Proteomics 19: 11–30, 2020. DOI: 10.1074/mcp.RA119.001677.L

"Heavily armed" pseudomonoas aeruginosa: mechanisms and genetic background of drug resistance.

Występujące powszechnie i narastające zjawisko oporności na antybiotyki wśród bakterii chorobotwórczych jest jednym z największych wyzwań dzisiejszej medycyny zakażeń. Szczególne zagrożenie stanowią zakażenia szpitalne wywoływane przez wielooporne szczepy określonych gatunków, np. Pseudomonas aeruginosa. Jest to patogen oportunistyczny, odznaczający się opornością naturalną na kilka klas stosowanych antybiotyków. Dzięki wysokiej plastyczności genomu, obejmującej różnorodne mutacje funkcjonalne (strukturalne i regulacyjne) oraz pozyskiwanie obcego DNA, jest w stanie szybko adaptować się do niesprzyjających warunków środowiska. Szczególnie niepokoi zdolność nabywania przez P. aeruginosa dodatkowych cech oporności, co w połączeniu z naturalnymi mechanizmami czyni ten patogen wybitnie trudnym do zwalczania. Bakteria ta jest w stanie wywoływać m. in. ostre zapalenie płuc, zakażenia łożyska krwi, skóry i tkanek miękkich (w tym ran operacyjnych i oparzeniowych). Jest również czynnikiem etiologicznym zakażeń przewlekłych, towarzyszących np. mukowiscydozie. Antybiotykami stosowanymi obecnie przeciwko zakażeniom P. aeruginosa są najczęściej cefalosporyny III i IV generacji, karbapenemy, fluorochinolony i aminoglikozydy. W związku z malejącą liczbą dostępnych, skutecznych opcji terapeutycznych pracuje się nad nowymi terapeutykami lub nowatorskim wykorzystywaniem dotąd już poznanych.The rapid spread of antibiotic resistance (AMR) in pathogenic bacteria is one of the greatest challenges of modern infectiology. In particular, the most threatening are nosocomial infections caused by multi-drug-resistant strains of several major species, such as Pseudomonas aeruginosa. This opportunistic pathogen exibits a broad-spectrum of natural resistance. Due to its high genome plasticity, comprising functional mutations and acquisition of foreign DNA, P. aeruginosa can easily adapt and persist in harsh environmental niches. The critical issue is its outstanding ability to acquire diverse AMR mechanisms, including those encoded by mobile genetic determinants. In addition to the intrinsic resistance, P. aeruginosa can be highly resistant to all of the currently available antipseudomonadal antimicrobials. P. aeruginosa is the etiological agent of a variety of infections, including acute pneumonia, bloodstream infections or skin and soft tissue infections (e. g. postoperative or burn wounds). It is responsible also for chronic infections, like those in cystic fibrosis (CF) patients. The major antimicrobials used in P. aeruginosa infections are newer-generation cephalosporins, carbapenems, fluoroquinolones or aminoglycosides. Owing to limitations of the effective therapeutic options against P. aeruginosa, new antimicrobials and novel indications and thus applications for older drugs are being developed

Effect of microbial UGmax enricher on soil physical and water retention properties

The paper presents the impact of UGmax enricher on soil physical and water retention properties. The experiment was established in 2005 in a 2 ha field 9 km from Lidzbark Warmiński in the village of Budniki. The studied soils were classified as Cambisols and Luvisols (IUSS Working Group WRB 2015), and they were formed from glaciolimnic deposits. Soil bulk density, soil particle density, texture, total porosity and water retention properties using low and high-pressure chambers were determined. The use of UGmax enricher on loamy soils used as arable lands in temperate climate of north-eastern Poland caused significant decrease of soil bulk density, increase of available water capacity and readily available water capacity. Statistically significant differences between examined soil properties were observed in most studied years

Genome-Based Epidemiologic Analysis of VIM/IMP Carbapenemase-Producing Enterobacter spp., Poland

We sequenced all nonduplicate 934 VIM/IMP carbapenemase-producing Enterobacterales (CPE) reported in Poland during 2006–2019 and found ≈40% of the isolates (n = 375) were Enterobacter spp. During the study period, incidence of those bacteria gradually grew in nearly the entire country. The major factor affecting the increase was clonal spread of several E. hormaechei lineages responsible for multiregional and interregional outbreaks (≈64% of all isolates), representing mainly the pandemic sequence type (ST) 90 or the internationally rare ST89 and ST121 clones. Three main VIM-encoding integron types efficiently disseminated across the clone variants (subclones) with various molecular platforms. Those variants were predominantly Pseudomonas aeruginosa–derived In238-like elements, present with IncHI2+HI2A, IncFII+FIA, IncFIB, or IncN3 plasmids, or chromosomal genomic islands in 30 Enterobacter STs. Another prevalent type, found in 34 STs, were In916-like elements, spreading in Europe recently with a lineage of IncA-like plasmids